Intellia Therapeutics’ (NTLA) Outperform Rating Reaffirmed at Wedbush

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a report released on Friday. They presently have a $36.00 price target on the stock. Wedbush’s target price suggests a potential upside of 38.57% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Chardan Capital upgraded Intellia Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday. BidaskClub upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday. Leerink Swann restated an “outperform” rating on shares of Intellia Therapeutics in a research report on Wednesday, March 14th. TheStreet downgraded Intellia Therapeutics from a “c-” rating to a “d” rating in a research report on Monday, May 7th. Finally, Cann restated a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, May 1st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Intellia Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $34.83.

NASDAQ:NTLA opened at $25.98 on Friday. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -13.82 and a beta of 2.85. Intellia Therapeutics has a 1 year low of $24.72 and a 1 year high of $25.64.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Tuesday, May 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.07. The firm had revenue of $7.47 million for the quarter, compared to the consensus estimate of $6.14 million. Intellia Therapeutics had a negative return on equity of 31.80% and a negative net margin of 278.64%. sell-side analysts forecast that Intellia Therapeutics will post -2 EPS for the current year.

In related news, insider John M. Leonard sold 8,400 shares of the stock in a transaction on Monday, May 14th. The stock was sold at an average price of $24.00, for a total value of $201,600.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jean Francois Formela sold 6,686 shares of the stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $25.04, for a total value of $167,417.44. The disclosure for this sale can be found here. Insiders sold 54,331 shares of company stock worth $1,305,796 in the last quarter. 12.80% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new stake in shares of Intellia Therapeutics in the first quarter worth $252,000. Barclays PLC raised its position in shares of Intellia Therapeutics by 112.8% in the first quarter. Barclays PLC now owns 19,778 shares of the company’s stock worth $416,000 after buying an additional 10,483 shares in the last quarter. UBS Group AG raised its position in shares of Intellia Therapeutics by 131.6% in the first quarter. UBS Group AG now owns 191,616 shares of the company’s stock worth $4,041,000 after buying an additional 108,878 shares in the last quarter. Platinum Investment Management Ltd. purchased a new stake in shares of Intellia Therapeutics in the first quarter worth $1,159,000. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Intellia Therapeutics in the first quarter worth $204,000. Institutional investors own 54.70% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mackay Shields LLC Acquires Shares of 30,300 LSC Communications
Mackay Shields LLC Acquires Shares of 30,300 LSC Communications
Mackay Shields LLC Invests $553,000 in Range Resources Corp.
Mackay Shields LLC Invests $553,000 in Range Resources Corp.
50,700 Shares in Immersion Co.  Purchased by Mackay Shields LLC
50,700 Shares in Immersion Co. Purchased by Mackay Shields LLC
SG Americas Securities LLC Takes $952,000 Position in Core-Mark Holding Company, Inc.
SG Americas Securities LLC Takes $952,000 Position in Core-Mark Holding Company, Inc.
Schlumberger Limited.  Position Boosted by Zeke Capital Advisors LLC
Schlumberger Limited. Position Boosted by Zeke Capital Advisors LLC
Aecon Group’s  “Outperform Overweight” Rating Reiterated at National Bank Financial
Aecon Group’s “Outperform Overweight” Rating Reiterated at National Bank Financial


Leave a Reply

 
© 2006-2018 Zolmax.